A Hard Choice For Abbreviated Biologics License Applicants
Much like the Hatch-Waxman Act provides a pathway for approving generic small-molecule drugs and litigating patent disputes about those drugs, the Biologics Price Competition and Innovation Act provides the same for...To view the full article, register now.
Already a subscriber? Click here to view full article